目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH DESIGN
2.2.1 SECONDARY RESEARCH
2.2.2 PRIMARY RESEARCH
2.2.2.1 Primary sources
2.2.2.2 Key industry insights
2.2.2.3 Breakdown of primaries
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
2.3.1.2 Approach 2: Customer-based market estimation
2.3.1.3 Approach 3: Top-down approach
2.3.1.4 Approach 4: Primary interviews
2.3.1.5 CAGR projections
2.4 DATA TRIANGULATION & MARKET BREAKDOWN
2.5 MARKET SHARE ASSESSMENT
2.6 STUDY ASSUMPTIONS
2.7 ASSUMPTIONS/MARKET FORECASTING METHODOLOGY
2.8 LIMITATIONS AND RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET OVERVIEW
4.2 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
4.3 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION AND END USER, 2023 (USD MILLION)
4.4 GEOGRAPHIC GROWTH OPPORTUNITIES IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising antimicrobial resistance
5.2.1.2 Advancements in diagnostic technologies
5.2.1.3 Expansion of clinical research applications
5.2.1.4 Rise in government initiatives
5.2.2 RESTRAINTS
5.2.2.1 High cost of automated instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Emergence of rapid testing solutions
5.2.3.2 Integration with digital health technologies
5.2.4 CHALLENGES
5.2.4.1 Intricate regulatory landscape
5.3 INDUSTRY TRENDS
5.3.1 ISOTHERMAL MICROCALORIMETRY
5.3.2 FLUORESCENCE-ACTIVATED CELL SORTING
5.3.3 SMARTPHONE-BASED OPTICAL SPECTROSCOPY
5.3.4 MICROFLUIDICS AND MICRODROPLETS
5.4 ECOSYSTEM ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.5.1 PROMINENT COMPANIES
5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES
5.5.3 END USERS
5.6 VALUE CHAIN ANALYSIS
5.7 PORTER'S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 BARGAINING POWER OF SUPPLIERS
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 THREAT OF SUBSTITUTES
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.8.2 BUYING CRITERIA
5.9 PATENT ANALYSIS
5.10 TRADE ANALYSIS
5.10.1 IMPORT DATA
5.10.2 EXPORT DATA
5.11 KEY CONFERENCES AND EVENTS, 2024-2025
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.13 TECHNOLOGY ANALYSIS
5.13.1 KEY TECHNOLOGIES
5.13.1.1 PCR
5.13.1.2 Microfluidics and lab-on-a-chip
5.13.1.3 Synthetic antimicrobial peptides
5.13.2 COMPLIMENTARY TECHNOLOGIES
5.13.2.1 MALDI-TOF
5.13.3 ADJACENT TECHNOLOGIES
5.13.3.1 Nanotechnology
5.13.3.2 Nanomotion technology
5.13.3.3 Biochip technology
5.14 REGULATORY LANDSCAPE
5.14.1 NORTH AMERICA
5.14.1.1 US
5.14.1.2 Canada
5.14.2 EUROPE
5.14.3 ASIA PACIFIC
5.14.3.1 Japan
5.14.3.2 China
5.14.3.3 India
5.14.4 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.15 INVESTMENT AND FUNDING SCENARIO
5.16 PRICING ANALYSIS
5.16.1 AVERAGE SELLING PRICE, BY REGION
5.16.2 AVERAGE SELLING PRICE, BY KEY PLAYER
5.17 REIMBURSEMENT SCENARIO
5.18 UNMET NEEDS AND KEY PAIN POINTS
5.19 IMPACT OF AI/GEN AI ON ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET

6 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 CULTURE & GROWTH MEDIA
6.2.1.1 High utilization of disk diffusion and broth dilution methods to drive market
6.2.2 SUSCEPTIBILITY TESTING DISKS
6.2.2.1 Low costs, ease of use to support adoption
6.2.3 MIC STRIPS
6.2.3.1 Accuracy, simplicity, and thorough results to drive usage
6.2.4 SUSCEPTIBILITY TESTING PLATES
6.2.4.1 Availability of specialized plates to drive market
6.3 LAB INSTRUMENTS
6.3.1 AUTOMATED LABORATORY INSTRUMENTS
6.3.1.1 Ongoing trend of laboratory automation to fuel segment growth
6.3.2 MOLECULAR DIAGNOSTICS SYSTEMS
6.3.2.1 Technological advancements in molecular diagnostics to propel market
6.4 LAB DISPOSABLES
6.4.1 INCREASING NUMBER OF SUSCEPTIBILITY TESTS PERFORMED IN HOSPITALS TO DRIVE DEMAND

7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE
7.1 INTRODUCTION
7.2 ANTIBACTERIAL SUSCEPTIBILITY TESTING
7.2.1 EMERGENCE OF MULTIDRUG-RESISTANCE TO INCREASE ADOPTION OF ANTIBACTERIAL SUSCEPTIBILITY TESTING PRODUCTS
7.3 ANTIFUNGAL SUSCEPTIBILITY TESTING
7.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO PROPEL DEMAND FOR TESTING
7.4 ANTIPARASITIC SUSCEPTIBILITY TESTING
7.4.1 RISING AWARENESS TO SUPPORT MARKET GROWTH
7.5 ANTIVIRAL SUSCEPTIBILITY TESTING
7.5.1 ADVANCEMENTS IN ANTIVIRAL SUSCEPTIBILITY TESTING TO ENHANCE PATIENT OUTCOMES

8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD
8.1 INTRODUCTION
8.2 QUALITATIVE METHODS
8.2.1 AUTOMATED AST
8.2.1.1 Advancements and resistance patterns to drive use of automated instruments
8.2.2 DISK DIFFUSION
8.2.2.1 Simplicity, accuracy, and flexibility to support adoption
8.2.3 AGAR DILUTION
8.2.3.1 Time-consuming and labor-intensive nature to affect adoption
8.2.4 GENOTYPIC METHOD
8.2.4.1 Gold standard status to support greater adoption
8.3 QUANTITATIVE METHODS
8.3.1 ETEST METHOD
8.3.1.1 Etest to hold larger share of quantitative methods market
8.3.2 BROTH MACRODILUTION
8.3.2.1 Precision, simultaneous testing capability to drive market

9 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION
9.1 INTRODUCTION
9.2 CLINICAL DIAGNOSTICS
9.2.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
9.3 DRUG DISCOVERY & DEVELOPMENT
9.3.1 EMPHASIS ON R&D AND INNOVATION TO SUPPORT DEMAND GROWTH
9.4 EPIDEMIOLOGY
9.4.1 NEED FOR BETTER UNDERSTANDING AND DECISION MAKING TO PROPEL ADOPTION
9.5 OTHER APPLICATIONS

10 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER
10.1 INTRODUCTION
10.2 HOSPITALS & DIAGNOSTIC CENTERS
10.2.1 HOSPITALS & DIAGNOSTIC CENTERS TO HOLD LARGEST MARKET SHARE
10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.3.1 EMPHASIS ON PRODUCT DEVELOPMENT TO DRIVE MARKET
10.4 ACADEMIC & RESEARCH INSTITUTES
10.4.1 RISING R&D ACTIVITY AND SUPPORT FOR RESEARCH TO DRIVE MARKET
10.5 CLINICAL RESEARCH ORGANIZATIONS
10.5.1 EXPANSION OF CLINICAL TRIALS WORLDWIDE TO PROPEL MARKET GROWTH

11 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
11.2.2 US
11.2.2.1 US to hold largest share of North American market
11.2.3 CANADA
11.2.3.1 Favorable government initiatives to drive market growth
11.3 EUROPE
11.3.1 EUROPE: MACROECONOMIC OUTLOOK
11.3.2 GERMANY
11.3.2.1 Government initiatives for AMR to drive market
11.3.3 FRANCE
11.3.3.1 Focus on enhancing AMR surveillance to propel market
11.3.4 UK
11.3.4.1 New action plans for AMR to propel adoption
11.3.5 ITALY
11.3.5.1 Rising instances of AMR and high use of antibiotics to propel demand for testing
11.3.6 SPAIN
11.3.6.1 Rising AMR in gram-negative bacilli to drive market
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
11.4.2 JAPAN
11.4.2.1 Industry-government collaborations for infectious disease management to support market growth
11.4.3 CHINA
11.4.3.1 Rising emphasis on AMR management to drive market
11.4.4 INDIA
11.4.4.1 Expanding government and industry efforts in clinical diagnostics to propel market growth
11.4.5 AUSTRALIA
11.4.5.1 Establishment and implementation of antimicrobial treatment guidelines to favor market growth
11.4.6 SOUTH KOREA
11.4.6.1 Need for rapid AMR detection to drive demand for automated AST systems
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
11.5.2 BRAZIL
11.5.2.1 Rising emphasis on implementing AMR detection to drive market
11.5.3 MEXICO
11.5.3.1 Economic growth to support expansion of AST systems
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
11.6.2 GCC COUNTRIES
11.6.2.1 Healthcare infrastructural development initiatives to support growth
11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
12.3 REVENUE ANALYSIS
12.4 MARKET SHARE ANALYSIS, 2023
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.5.5.1 Company footprint
12.5.5.2 Region footprint
12.5.5.3 Product footprint
12.5.5.4 Type footprint
12.5.5.5 Method footprint
12.5.5.6 Application footprint
12.5.5.7 End-user footprint
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.7 VALUATION & FINANCIAL METRICS
12.7.1 FINANCIAL METRICS
12.7.2 COMPANY VALUATION
12.8 BRAND/PRODUCT COMPARISON
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES & APPROVALS
12.9.2 DEALS

13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 BIOMERIEUX SA
13.1.1.1 Business overview
13.1.1.2 Products offered
13.1.1.3 Recent developments
13.1.1.3.1 Product launches & approvals
13.1.1.3.2 Deals
13.1.1.4 MnM view
13.1.1.4.1 Right to win
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses & competitive threats
13.1.2 BECTON, DICKINSON AND COMPANY
13.1.2.1 Business overview
13.1.2.2 Products offered
13.1.2.3 Recent developments
13.1.2.3.1 Deals
13.1.2.3.2 Other developments
13.1.2.4 MnM view
13.1.2.4.1 Right to win
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses and competitive threats
13.1.3 THERMO FISHER SCIENTIFIC INC.
13.1.3.1 Business overview
13.1.3.2 Products offered
13.1.3.3 Recent developments
13.1.3.3.1 Product launches & approvals
13.1.3.3.2 Deals
13.1.3.4 MnM view
13.1.3.4.1 Right to win
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses and competitive threats
13.1.4 DANAHER CORPORATION
13.1.4.1 Business overview
13.1.4.2 Products offered
13.1.4.3 Recent developments
13.1.4.3.1 Product launches & approvals
13.1.4.3.2 Deals
13.1.4.4 MnM view
13.1.4.4.1 Right to win
13.1.4.4.2 Strategic choices
13.1.4.4.3 Weaknesses and competitive threats
13.1.5 BIO-RAD LABORATORIES, INC.
13.1.5.1 Business overview
13.1.5.2 Products offered
13.1.5.2.1 Deals
13.1.5.3 MnM view
13.1.5.3.1 Right to win
13.1.5.3.2 Strategic choices
13.1.5.3.3 Weaknesses and competitive threats
13.1.6 BRUKER
13.1.6.1 Business overview
13.1.6.2 Products offered
13.1.6.3 Recent developments
13.1.6.3.1 Product launches & approvals
13.1.6.3.2 Deals
13.1.7 ROCHE DIAGNOSTICS
13.1.7.1 Business overview
13.1.7.2 Products offered
13.1.7.3 Recent developments
13.1.7.3.1 Product launches & approvals
13.1.7.3.2 Deals
13.1.8 MERCK KGAA
13.1.8.1 Business overview
13.1.8.2 Products offered
13.1.8.3 Recent developments
13.1.8.3.1 Deals
13.1.9 ACCELERATE DIAGNOSTICS, INC.
13.1.9.1 Business overview
13.1.9.2 Products offered
13.1.9.3 Recent developments
13.1.9.3.1 Product launches & approvals
13.1.9.3.2 Deals
13.1.9.3.3 Other developments
13.1.10 HIMEDIA LABORATORIES
13.1.10.1 Business overview
13.1.10.2 Products offered
13.1.11 LIOFILCHEM S.R.L.
13.1.11.1 Business overview
13.1.11.2 Products offered
13.1.12 ALIFAX S.R.L.
13.1.12.1 Business overview
13.1.12.2 Products offered
13.1.13 CREATIVE DIAGNOSTICS
13.1.13.1 Business overview
13.1.13.2 Products offered
13.1.14 SYNBIOSIS
13.1.14.1 Business overview
13.1.14.2 Products offered
13.1.15 BIOANALYSE
13.1.15.1 Business overview
13.1.15.2 Products offered
13.2 OTHER KEY PLAYERS
13.2.1 ZHUHAI DL BIOTECH CO., LTD.
13.2.2 ELITECHGROUP
13.2.3 MAST GROUP LTD.
13.2.4 CONDALAB
13.2.5 GENEFLUIDICS, INC.
13.2.6 BIOTRON HEALTHCARE
13.2.7 INVIVOGEN
13.2.8 MP BIOMEDICALS
13.2.9 QUANTAMATRIX INC.
13.2.10 SYSMEX EUROPE SE
13.2.11 COPAN DIAGNOSTICS INC.
13.2.12 ERBA DIAGNOSTICS MANNHEIM GMBH

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS